Therefore, systemic treatments with programmed death‐(ligand)1 (PD‐[L]1) inhibitors plus anti‐vascular endothelial growth factor (anti‐VEGF) antibody/tyrosine kinase inhibitors (TKIs)/anti‐CTLA4 antibodies are recommended as first‐line treatment for advanced HCC [3, 4]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.